NAMS in the 13F filings
Newamsterdam Pharma Company · CUSIP N62509109
- Quarter end
- 30 Jun 2025
- the date the book describes
- Filed
- 14 Aug 2025
- latest of these filings; the earliest 13 Aug 2025
- Managers listing it
- 5
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q1 2025 and Q2 2025; 5 listed it in both
- Shares listed
- 20,757,390
- combined, among listed positions
- Reported value
- $376m
- combined, at the quarter end
Among the 95 comparable managers: 2 buyers (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +2,026,332.
Managers listing NAMS in Q2 2025
5 of 5 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Capital World Investors | 8,387,725 | $152m | under 0.1% | Added | +1,589,127 | 13 Aug 2025 (the filing on sec.gov) |
| Viking Global Investors LP | 6,978,534 | $126m | 0.37% | Held | 0 | 14 Aug 2025 (the filing on sec.gov) |
| Janus Henderson Group Ltd | 1,962,060 | $36m | under 0.1% | Trimmed | -237,573 | 14 Aug 2025 (the filing on sec.gov) |
| Woodline Partners LP | 1,897,197 | $34m | 0.18% | Trimmed | -545,200 | 14 Aug 2025 (the filing on sec.gov) |
| Maverick Capital Ltd | 1,531,874 | $28m | 0.42% | Added | +982,405 | 14 Aug 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Capital World Investorsexisting position · 8,387,725 shares now+1,589,127
- Maverick Capital Ltdexisting position · 1,531,874 shares now+982,405
Reductions
- Woodline Partners LPexisting position · 1,897,197 shares now-545,200
- Janus Henderson Group Ltdexisting position · 1,962,060 shares now-237,573
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2022 | 1 | $39m | n.a. | n.a. |
| Q1 2023 | 1 | $53m | n.a. | n.a. |
| Q2 2023 | 1 | $78m | n.a. | n.a. |
| Q3 2023 | 1 | $74m | n.a. | n.a. |
| Q4 2023 | 1 | $90m | 0 | 0 |
| Q1 2024 | 1 | $190m | 0 | 0 |
| Q2 2024 | 2 | $163m | 1 | 0 |
| Q3 2024 | 2 | $153m | 1 | 0 |
| Q4 2024 | 5 | $322m | 4 | 1 |
| Q1 2025 | 5 | $391m | 4 | 0 |
| Q2 2025 | 5 | $376m | 2 | 2 |
| Q3 2025 | 5 | $599m | 2 | 3 |
| Q4 2025 | 8 | $851m | 17 | 5 |
| Q1 2026 | 6 | $820m | 13 | 11 |
| Q2 2026 | 6 | $790m | 21 | 6 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
NAMS and LLY →NAMS and JNJ →NAMS and VRTX →Choose a stock to compare with NAMS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own NAMS, latest filings →Back to the 13F Explorer →